A total of 5,841 patients with AMI hospitalized in 14 coronary care units in Israel are included in the SPRINT Registry. Of these, 2,276 patients were randomized to receive nifedipine or placebo from 7 to 21 days after die onset of the AMI, and comprise the subjects in the SPRINT Registry. Detailed information was available on clinical and laboratory findings in these patients as well as for an additional 3,565 AMI patients who were excluded from the trial by exclusion criteria but are included in the SPRINT Registry. A follow-up study after at least one year was performed on the patients in this registry. Patient data were recorded on specially designed forms and stored in a computer. buy cheap antibiotics
The following information was extracted for all the patients studied—age, sex, significant arrhythmias occurring while in the coronary care unit, presence of CHF on admission or developing while in the hospital, presence of cardiogenic shock or systolic blood pressure below 90 mm Hg (persistent for more than 48 h), frequency of peak levels of cardiac enzymes (CPK, SGOT and LDH) four or more times the upper limit of normal and hospital and one-year mortality. The one-year follow-up for hospital survivors was 99 percent complete. The mortality was related to the presence or absence of major arrhythmias, cardiac failure, cardiogenic shock, persistent hypotension and to an empiric entity of “pump failure.” This was defined as the presence of symptoms or signs or of radiologic features, of CHF on admission, or their development during the patients stay in the hospital or the presence of cardiogenic shock; or the presence of hypotension (systolic blood pressure below 90 mm Hg) persisting 48 h or more; or any combination of the foregoing.